Dermata Therapeutics, Inc. Board of Directors

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Mr. Gerald T. Proehl

Mr. Gerald T. Proehl

Founder, President, CEO & Chairman

Dr. Christopher J. Nardo M.P.H., Ph.D.

Dr. Christopher J. Nardo M.P.H., Ph.D.

Senior VP & Chief Development Officer

Mr. David F. Hale

Mr. David F. Hale

Co-Founder & Lead Independent Director

Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.

Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.

Senior Vice President of Regulatory Affairs & Quality Assurance

Mr. Sean Proehl

Mr. Sean Proehl

Senior Director of Legal & Business Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.